The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Apr

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs

Japanese Study Looks at Rates of Cancer Therapy–Related AML

Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome

Final Report on Pralsetinib in Advanced RET Fusion–Positive NSCLC

New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research